SG158919A1 - Constructs binding to phosphatidylserine and their use in disease treatment - Google Patents
Constructs binding to phosphatidylserine and their use in disease treatmentInfo
- Publication number
- SG158919A1 SG158919A1 SG201000541-1A SG2010005411A SG158919A1 SG 158919 A1 SG158919 A1 SG 158919A1 SG 2010005411 A SG2010005411 A SG 2010005411A SG 158919 A1 SG158919 A1 SG 158919A1
- Authority
- SG
- Singapore
- Prior art keywords
- phosphatidylserine
- new
- disclosed
- constructs
- disease treatment
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 title abstract 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012216 imaging agent Substances 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 210000005166 vasculature Anatomy 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
- A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nanotechnology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Marine Sciences & Fisheries (AREA)
- Crystallography & Structural Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64633305P | 2005-01-24 | 2005-01-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG158919A1 true SG158919A1 (en) | 2010-02-26 |
Family
ID=36693034
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG201000541-1A SG158919A1 (en) | 2005-01-24 | 2006-01-24 | Constructs binding to phosphatidylserine and their use in disease treatment |
Country Status (14)
Country | Link |
---|---|
US (3) | US8956616B2 (fr) |
EP (1) | EP1853631B1 (fr) |
JP (2) | JP5127043B2 (fr) |
CN (3) | CN104277117A (fr) |
AU (1) | AU2006206187B2 (fr) |
CA (1) | CA2591914C (fr) |
DK (1) | DK1853631T3 (fr) |
ES (1) | ES2565543T3 (fr) |
HK (2) | HK1198255A1 (fr) |
IL (1) | IL184406A (fr) |
NZ (1) | NZ556065A (fr) |
SG (1) | SG158919A1 (fr) |
SI (1) | SI1853631T1 (fr) |
WO (1) | WO2006079120A2 (fr) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090291086A1 (en) * | 2001-02-21 | 2009-11-26 | Alavita Pharmaceuticals, Inc. | Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia |
US20050222030A1 (en) * | 2001-02-21 | 2005-10-06 | Anthony Allison | Modified annexin proteins and methods for preventing thrombosis |
GB0707034D0 (en) | 2007-04-12 | 2007-05-23 | St Andrews The | Compounds |
US9163091B2 (en) * | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
US20110064744A1 (en) * | 2007-05-30 | 2011-03-17 | Sabbadini Roger A | Prevention and treatment of pain using antibodies to lysophosphatidic acid |
DK2164992T3 (en) * | 2007-05-30 | 2016-08-15 | Lpath Inc | COMPOSITIONS AND METHODS FOR BONDING OF LYTHOPHOSPHATIC ACID |
WO2009049083A1 (fr) | 2007-10-09 | 2009-04-16 | Washington University In St. Louis | Particules d'imagerie |
WO2009049089A1 (fr) | 2007-10-09 | 2009-04-16 | Washington University In St. Louis | Nanoparticules toroïdales dirigées ligand pour thérapie et imagerie de diagnostic |
US20110160642A1 (en) * | 2007-11-15 | 2011-06-30 | Wolfgang Neuberger | Pegylated liposomal formulations for photodynamic treatment of inflammatory diseases |
GB0723797D0 (en) | 2007-12-05 | 2008-01-16 | Immunosolv Ltd | Method |
WO2009089098A1 (fr) * | 2008-01-03 | 2009-07-16 | Musc Foundation For Research Development | Traitements anticancéreux |
CN102046151A (zh) * | 2008-03-26 | 2011-05-04 | 牛津大学 | 靶向内质网的脂质体 |
GB0819287D0 (en) | 2008-10-22 | 2008-11-26 | Univ Bradford | Compounds |
AU2009322145A1 (en) * | 2008-12-05 | 2011-06-23 | Abraxis Bioscience, Llc | SPARC Binding ScFvs |
WO2011036467A1 (fr) * | 2009-09-24 | 2011-03-31 | Russell David Keenan | Produits utiles dans le traitement de l'hémophilie |
WO2011069090A1 (fr) * | 2009-12-04 | 2011-06-09 | Alavita Pharmaceuticals, Inc. | Inhibition de l'activation du facteur xii de la coagulation par des ligands de phosphatidylsérine |
US9808500B2 (en) | 2009-12-17 | 2017-11-07 | Washington University | Antithrombotic nanoparticle |
US9764043B2 (en) | 2009-12-17 | 2017-09-19 | Washington University | Antithrombotic nanoparticle |
EP2369551B1 (fr) * | 2010-03-25 | 2019-10-30 | Emory University | Système et procédé d'imagerie |
AU2011239414A1 (en) | 2010-04-15 | 2012-11-08 | The Washington University | Prodrug compositions, prodrug nanoparticles, and methods of use thereof |
CN103124788B (zh) | 2010-05-21 | 2016-01-13 | 梅里麦克制药股份有限公司 | 双特异性融合蛋白 |
CN105524176B (zh) * | 2010-05-21 | 2021-03-19 | 银溪制药股份有限公司 | 双特异性融合蛋白 |
WO2012030949A2 (fr) * | 2010-09-01 | 2012-03-08 | Kansas State University Research Foundation | Inhibiteurs peptidiques de la β2-glycoprotéine i |
EP2750662A4 (fr) | 2011-08-31 | 2015-06-24 | Univ Georgia | Nanoparticules ciblant l'apoptose |
US9463217B1 (en) * | 2012-02-10 | 2016-10-11 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Methods and pharmaceutical compositions for treatment of retinal occlusion |
US10416167B2 (en) | 2012-02-17 | 2019-09-17 | University Of Georgia Research Foundation, Inc. | Nanoparticles for mitochondrial trafficking of agents |
EP3184121A3 (fr) * | 2012-07-25 | 2017-09-27 | Salk Institute For Biological Studies | Régulation de l'interaction entre les ligands de tam et les membranes lipidiques contenant de la phosphatidylsérine |
US20140287024A1 (en) * | 2013-03-08 | 2014-09-25 | Shu Wang | Nanoparticle-based delivery system with oxidized phospholipids as targeting ligands for the prevention, diagnosis and treatment of atherosclerosis |
DK3524617T3 (da) * | 2013-03-15 | 2023-05-15 | Gladiator Biosciences Inc | Gla-domæner som terapeutiske midler |
GB2516882A (en) | 2013-08-02 | 2015-02-11 | Univ Bradford | Tumour-targeted theranostic |
EP3083946B1 (fr) | 2013-12-16 | 2024-08-07 | The University of North Carolina at Chapel Hill | Déplétion de cellules dendritiques plasmacytoïdes |
US10398663B2 (en) | 2014-03-14 | 2019-09-03 | University Of Georgia Research Foundation, Inc. | Mitochondrial delivery of 3-bromopyruvate |
JP6779866B2 (ja) | 2014-06-13 | 2020-11-04 | チルドレンズ メディカル センター コーポレイション | ミトコンドリアを単離するための製品および方法 |
US11000603B2 (en) | 2015-04-14 | 2021-05-11 | Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. | Multi-specific binding conjugate, related pharmaceutical compositions and use |
WO2016179430A1 (fr) * | 2015-05-05 | 2016-11-10 | Rubicon Biotechnology Llc | Immunothérapie du cancer |
CA2988771A1 (fr) * | 2015-06-09 | 2016-12-15 | The Board Of Regents Of The University Of Texas System | Test de diagnostic pour le cancer a un stade precoce |
CN108367048B (zh) | 2015-10-02 | 2022-08-12 | 银溪制药股份有限公司 | 用于组织修复的双特异性治疗性蛋白质 |
IL310404A (en) * | 2015-12-15 | 2024-03-01 | Oncoc4 Inc | Chimeric and humanized monoclonal antibodies against CTLA-4 and uses thereof |
CN109152795A (zh) * | 2016-01-15 | 2019-01-04 | 儿童医学中心公司 | 线粒体和组合的线粒体试剂的治疗用途 |
WO2017133018A1 (fr) * | 2016-02-06 | 2017-08-10 | 法玛科技顾问股份有限公司 | Peptide de bêta 2-glycoprotéine de recombinaison et application antitumorale associée |
CN109195992A (zh) * | 2016-04-29 | 2019-01-11 | 本康生物制药(深圳)有限公司 | 多特异性结合偶联物、相关的药物组合物及应用 |
US11525009B2 (en) | 2016-06-22 | 2022-12-13 | Benhealth Biopharmaceutic (Shenzhen) Co. Ltd. | Bispecific antibody and antibody conjugate for tumor therapy and use thereof |
EA038617B1 (ru) * | 2016-07-06 | 2021-09-23 | Онкоиммьюн, Инк. | Химерные и гуманизированные античеловеческие ctla-4 моноклональные антитела и их использование |
MX2019003569A (es) * | 2016-09-27 | 2020-07-22 | Oncologie Inc | Metodos para tratar el cancer con bavituximab en funcion de niveles de b2 glucoproteina 1 y ensayos de estos. |
CN110036033B (zh) | 2016-09-27 | 2023-12-08 | 森罗治疗公司 | 嵌合吞噬受体分子 |
WO2018187227A1 (fr) | 2017-04-03 | 2018-10-11 | Concologie, Inc. | Procédés de traitement du cancer à l'aide d'anticorps ciblant ps avec des agents immuno-oncologiques |
CN108727489B (zh) * | 2017-04-19 | 2021-02-09 | 广州市第八人民医院 | 一种单克隆抗体zk2c2及应用 |
JP7221545B2 (ja) * | 2017-07-24 | 2023-02-14 | ラトガース,ザ ステート ユニバーシティ オブ ニュー ジャージー | ホスファチジルセリン標的化融合分子およびそれらの使用方法 |
WO2019028336A1 (fr) * | 2017-08-03 | 2019-02-07 | The Cleveland Clinic Foundation | Expression peptidique améliorée et détection d'anticorps de sujet spécifique d'apo-h |
PE20201462A1 (es) * | 2017-09-05 | 2020-12-17 | Gladiator Biosciences Inc | Metodo de direccionamiento de exosomas |
KR20200100598A (ko) | 2017-09-26 | 2020-08-26 | 세로 테라퓨틱스, 인코포레이티드 | 키메라 포식작용 수용체 분자 및 사용 방법 |
CN108021784B (zh) * | 2017-12-01 | 2021-05-11 | 大连理工大学 | 纳米金属氧化物光致产生活性氧物种的预测方法 |
ES2727261B2 (es) * | 2018-04-12 | 2020-05-06 | Fundacion Para La Investig Biomedica Del Hospital 12 De Octubre | INMUNOCOMPLEJOS ARTIFICIALES Y SU USO COMO CALIBRES EN SISTEMAS DE DETECCION DE INMUNOCOMPLEJOS CIRCULANTES B2GP1-aB2GP1 |
WO2020097165A1 (fr) * | 2018-11-08 | 2020-05-14 | Nasr Mahmoud | Nanodisques pour la prévention et le traitement d'infections pathogènes et leurs procédés d'utilisation |
TW202039583A (zh) | 2018-12-07 | 2020-11-01 | 瑞士商巴克斯歐塔有限公司 | 結合因子IXa及因子X的蛋白分子 |
WO2020114614A1 (fr) | 2018-12-07 | 2020-06-11 | Baxalta GmbH | Molécules protéiques se liant au facteur ixa et au facteur x |
EP3711772A1 (fr) * | 2019-03-20 | 2020-09-23 | Oslo Universitetssykehus HF | Protéines recombinantes et protéines de fusion |
WO2020264181A1 (fr) * | 2019-06-28 | 2020-12-30 | The Board Of Regents Of The University Of Oklahoma | Conjugués d'annexine-médicament thérapeutiques et procédés d'utilisation |
US20220033426A1 (en) * | 2020-07-28 | 2022-02-03 | Yale University | Transition Metal Macrocyclics as MRI Contrast Agents for Molecular Imaging |
WO2022040635A1 (fr) * | 2020-08-21 | 2022-02-24 | The University Of Chicago | Nanoparticules contenant de multiples promédicaments clivables pour la thérapie du cancer |
WO2022170145A1 (fr) * | 2021-02-05 | 2022-08-11 | Viqi, Inc. | Apprentissage machine pour la détection précoce de changements morphologiques cellulaires |
CN114002133B (zh) * | 2021-10-25 | 2023-01-24 | 南京大学 | 血清中ps阳性外泌体作为乳腺癌化疗敏感性标志物的应用 |
AU2023209872A1 (en) * | 2022-01-19 | 2024-08-01 | Lyndra Therapeutics, Inc. | Dosage forms for gastric retention |
CN114288399B (zh) * | 2022-01-20 | 2023-10-27 | 武汉科技大学 | 一种嵌合抗原受体联合抗肿瘤药物组合物及其应用 |
US20230324382A1 (en) * | 2022-02-01 | 2023-10-12 | Trustees Of Tufts College | Antiphospholipid antibodies for the diagnosis of lyme disease |
WO2023150672A1 (fr) * | 2022-02-04 | 2023-08-10 | Duke University | Compositions et méthodes de traitement de cancers hématologiques |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5245015A (en) * | 1991-04-26 | 1993-09-14 | Tanox Biosystems, Inc. | Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro |
CA2058769C (fr) | 1990-04-06 | 1999-03-02 | Steven Anthony Krilis | Methodes pour le dosage des phospholipides et de leurs anticorps |
ES2126644T3 (es) | 1992-02-05 | 1999-04-01 | Yamasa Corp | Reactivo en fase solida y dosificado anticorporal que lo utiliza. |
WO1994013323A1 (fr) | 1992-12-04 | 1994-06-23 | The Liposome Company, Inc. | Methode d'inhibition de la clairance des liposomes contenus dans la circulation |
FR2701319B1 (fr) | 1993-02-09 | 1995-04-21 | Elie Stefas | Procédé de détection et/ou de dosage de composés viraux et support portant une glycoprotéine. |
FR2701263B1 (fr) | 1993-02-09 | 1995-04-21 | Elie Stefas | Procédé d'obtention d'une composition aqueuse protéinique, composition correspondante, glycoprotéine contenue et son utilisation pour la stabilisation de l'albumine et la détection ou le dosage d'anticorps. |
AU7707294A (en) | 1993-09-29 | 1995-04-18 | Yamasa Corporation | Method of assaying oxidized lipoprotein and application thereof |
CA2176007A1 (fr) | 1993-11-16 | 1995-05-26 | Eiji Matsuura | Procede pour le dosage d'anticorps antiphospholipides et kit associe |
FR2722991B1 (fr) | 1994-08-01 | 1996-10-11 | Orstom | Utilisation de la beta2-glycoproteine i sous au moins une de ses formes comme agent anti-infectueux et composition pharmaceutique corrrespondante |
ES2179879T3 (es) | 1994-08-01 | 2003-02-01 | Inst Rech Developpement Ird | Procedimiento de separacion y/o de deteccion y/o de cuantificacion de compuesto(s) infeccioso(s) y soporte para la realizacion de dicho procedimiento. |
US5817789A (en) | 1995-06-06 | 1998-10-06 | Transkaryotic Therapies, Inc. | Chimeric proteins for use in transport of a selected substance into cells |
US5874409A (en) | 1995-06-07 | 1999-02-23 | La Jolla Pharmaceutical Company | APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies |
US6203980B1 (en) | 1998-02-02 | 2001-03-20 | University Of Pittsburgh | Identification of apolipoprotein H mutations and their diagnostic uses |
US6858210B1 (en) | 1998-06-09 | 2005-02-22 | La Jolla Pharmaceutical Co. | Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same |
IL125262A0 (en) | 1998-07-07 | 1999-03-12 | Yeda Res & Dev | Synthetic peptides and pharmaceutical compositions comprising them |
JP2000028607A (ja) | 1998-07-10 | 2000-01-28 | Iatron Lab Inc | 新規なモノクローナル抗体及びニックβ2グリコプロテインIの免疫学的分析方法 |
AU771224B2 (en) | 1998-07-13 | 2004-03-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
US6406693B1 (en) | 1998-07-13 | 2002-06-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
ATE230614T1 (de) | 1998-07-13 | 2003-01-15 | Univ Texas | Krebsbehandlung mit aminophospholipide bindenden, therapeutischen konjugaten |
US6818213B1 (en) | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
US20050148499A1 (en) | 1998-10-04 | 2005-07-07 | Dror Harats | Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of atherosclerosis |
US20050197283A1 (en) | 1998-10-04 | 2005-09-08 | Vascular Biogenics Ltd. | Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease |
IL126447A (en) | 1998-10-04 | 2004-09-27 | Vascular Biogenics Ltd | An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis |
AUPQ272699A0 (en) | 1999-09-09 | 1999-09-30 | Unisearch Limited | Use of beta2GPI in diagnostic tests for autoimmune diseases |
US7600039B2 (en) * | 2000-02-16 | 2009-10-06 | Motorola, Inc. | Label-based multiplexing |
JP2004500099A (ja) | 2000-03-08 | 2004-01-08 | ナショナル ジューイッシュ メディカル アンド リサーチ センター | ホスファチジルセリンレセプターおよびその使用 |
AU2001268228A1 (en) | 2000-06-08 | 2001-12-17 | La Jolla Pharmaceutical Company | Multivalent platform molecules comprising high molecular weight polyethylene oxide |
EP2354149B1 (fr) * | 2000-12-12 | 2017-08-30 | MedImmune, LLC | Molécules à demi-vies longues, compositions et utilisations de celles-ci |
ES2296914T3 (es) * | 2001-01-26 | 2008-05-01 | The General Hospital Corporation | Farmacos de serpina para el tratamiento de la infeccion por vih y metodo de uso de los mismos. |
JP4351041B2 (ja) | 2001-06-13 | 2009-10-28 | ザ・ユニバーシティ・オブ・シドニー | 傷治癒のための処置および組成物 |
FR2827047B1 (fr) | 2001-07-03 | 2003-09-26 | Apoh Technollgies Sa | Procede de separation et/ou detection et/ou identification et/ou quantification de proteines prions |
JP4681175B2 (ja) | 2001-09-28 | 2011-05-11 | 三菱化学メディエンス株式会社 | 播種性血管内凝固症候群及びその発症前段階を検出する方法 |
JP4070443B2 (ja) | 2001-10-11 | 2008-04-02 | 株式会社三菱化学ヤトロン | 脳梗塞を検出する方法 |
US20030100036A1 (en) | 2001-11-08 | 2003-05-29 | Aristo Vojdani | Saliva immunoassay for detection of antibodies for cardiovascular disease |
WO2003044482A2 (fr) | 2001-11-16 | 2003-05-30 | The University Of Tennessee Research Corporation | Proteines de fusion d'anticorps de recombinaison et procedes de detection de cellules apoptotiques |
EP1515754B1 (fr) | 2002-05-17 | 2011-05-25 | Board Of Regents, The University Of Texas System | La beta-2-glycoproteine 1 est un inhibiteur de l'angiogenese |
US7678386B2 (en) | 2002-07-15 | 2010-03-16 | Board Of Regents The University Of Texas | Liposomes coated with selected antibodies that bind to aminophospholipids |
US7906115B2 (en) | 2002-07-15 | 2011-03-15 | Thorpe Philip E | Combinations kits and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
US7247303B2 (en) | 2002-07-15 | 2007-07-24 | Board Of Regents, The University Of Texas System | Selected antibody CDRs for binding to aminophospholipids |
US7622118B2 (en) | 2002-07-15 | 2009-11-24 | Board Of Regents, The University Of Texas System | Cancer treatment methods using selected antibodies to aminophospholipids |
DK2269656T3 (da) | 2002-07-15 | 2014-11-03 | Univ Texas | Udvalgte antistoffer, som binder til aminophospholipider og deres anvendelse i behandling, så som cancer |
US7455833B2 (en) | 2002-07-15 | 2008-11-25 | Board Of Regents, The University Of Texas System | Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
US7572448B2 (en) | 2002-07-15 | 2009-08-11 | Board Of Regents, The University Of Texas System | Combined cancer treatment methods using selected antibodies to aminophospholipids |
US7625563B2 (en) | 2002-07-15 | 2009-12-01 | Board Of Regents, The University Of Texas System | Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids |
US7611704B2 (en) | 2002-07-15 | 2009-11-03 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
US7790159B2 (en) | 2002-07-15 | 2010-09-07 | Board Of Regents, The University Of Texas System | Methods, combinations and kits for treating viral infections using immunoconjugates and antibodies to aminophospholipids |
US7714109B2 (en) | 2002-07-15 | 2010-05-11 | Board Of Regents, The University Of Texas System | Combinations and kits for cancer treatment using selected antibodies to aminophospholipids |
US7615223B2 (en) | 2002-07-15 | 2009-11-10 | Board Of Regents, The University Of Texas System | Selected immunoconjugates for binding to aminophospholipids |
ATE512364T1 (de) | 2002-08-07 | 2011-06-15 | Ablynx Nv | Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha |
EP2298347B1 (fr) | 2003-05-06 | 2015-09-30 | Biogen Hemophilia Inc. | Protéines chimériques du facteur de la coagulation pour le traitement d'un trouble de l'hémostase |
US8198020B2 (en) | 2003-08-22 | 2012-06-12 | Potentia Pharmaceuticals, Inc. | Compositions and methods for enhancing phagocytosis or phagocyte activity |
EP1874334A4 (fr) | 2005-04-15 | 2011-03-30 | Vascular Biogenics Ltd | Compositions contenant des peptides derives de la glycoproteine i beta 2 pour la prevention et le traitement de maladie cardiovasculaire |
CA2603814C (fr) | 2005-04-18 | 2013-08-27 | Bio-Rad Laboratories, Inc. | Immobilisation en phase solide de phospholipides et de proteines cofacteur via liaison covalente |
-
2006
- 2006-01-24 CN CN201410333397.6A patent/CN104277117A/zh not_active Withdrawn
- 2006-01-24 SG SG201000541-1A patent/SG158919A1/en unknown
- 2006-01-24 NZ NZ556065A patent/NZ556065A/en unknown
- 2006-01-24 ES ES06719706.1T patent/ES2565543T3/es active Active
- 2006-01-24 CN CNA2006800070648A patent/CN101146826A/zh active Pending
- 2006-01-24 DK DK06719706.1T patent/DK1853631T3/en active
- 2006-01-24 JP JP2007552418A patent/JP5127043B2/ja not_active Expired - Fee Related
- 2006-01-24 US US11/339,392 patent/US8956616B2/en active Active
- 2006-01-24 WO PCT/US2006/002964 patent/WO2006079120A2/fr active Application Filing
- 2006-01-24 AU AU2006206187A patent/AU2006206187B2/en not_active Ceased
- 2006-01-24 EP EP06719706.1A patent/EP1853631B1/fr not_active Not-in-force
- 2006-01-24 SI SI200632035T patent/SI1853631T1/sl unknown
- 2006-01-24 CA CA2591914A patent/CA2591914C/fr not_active Expired - Fee Related
- 2006-01-24 CN CN201410301233.5A patent/CN104109209B/zh not_active Expired - Fee Related
-
2007
- 2007-07-04 IL IL184406A patent/IL184406A/en not_active IP Right Cessation
-
2012
- 2012-03-14 JP JP2012057880A patent/JP2012111783A/ja not_active Withdrawn
-
2014
- 2014-11-21 HK HK14111797.6A patent/HK1198255A1/zh not_active IP Right Cessation
-
2015
- 2015-02-02 US US14/611,634 patent/US20160015826A1/en not_active Abandoned
- 2015-06-05 HK HK15105389.1A patent/HK1205133A1/xx unknown
-
2016
- 2016-07-12 US US15/207,955 patent/US20160311886A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN104109209B (zh) | 2016-06-08 |
WO2006079120A3 (fr) | 2007-07-19 |
HK1198255A1 (zh) | 2015-03-20 |
EP1853631A2 (fr) | 2007-11-14 |
IL184406A (en) | 2014-11-30 |
AU2006206187A1 (en) | 2006-07-27 |
JP2008528521A (ja) | 2008-07-31 |
EP1853631B1 (fr) | 2016-03-09 |
WO2006079120A2 (fr) | 2006-07-27 |
JP5127043B2 (ja) | 2013-01-23 |
JP2012111783A (ja) | 2012-06-14 |
IL184406A0 (en) | 2008-12-29 |
US20160311886A1 (en) | 2016-10-27 |
CN101146826A (zh) | 2008-03-19 |
ES2565543T3 (es) | 2016-04-05 |
DK1853631T3 (en) | 2016-03-29 |
CA2591914A1 (fr) | 2006-07-27 |
US20160015826A1 (en) | 2016-01-21 |
NZ556065A (en) | 2009-04-30 |
AU2006206187B2 (en) | 2011-03-10 |
CN104109209A (zh) | 2014-10-22 |
SI1853631T1 (sl) | 2016-04-29 |
HK1205133A1 (en) | 2015-12-11 |
CA2591914C (fr) | 2017-04-25 |
US20060228299A1 (en) | 2006-10-12 |
CN104277117A (zh) | 2015-01-14 |
US8956616B2 (en) | 2015-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG158919A1 (en) | Constructs binding to phosphatidylserine and their use in disease treatment | |
WO2004113571A3 (fr) | Genes specifiques de la prostate et leur utilisation comme cibles dans le traitement et le diagnostic du cancer de la prostate | |
WO2010046900A3 (fr) | Peptidomimétiques contenant rgd et leurs utilisations | |
WO2008008483A3 (fr) | Compositions basées sur dendrimères et procédés d'utilisation correspondants | |
EP4279140A3 (fr) | Anticorps humains du facteur tissulaire | |
RS20150135A1 (en) | TREATMENT WITH ANTI-VEGF ANTIBODIES | |
WO2006033766A3 (fr) | Compositions a base de dendrimeres et procedes d'utilisation de celles-ci | |
SG153825A1 (en) | Multivalent immunoglobulin-based bioactive assemblies | |
MX2007012817A (es) | Eliminacion de poblacion celular heterogenea o mezclada en tumores. | |
WO2006093967A3 (fr) | Compositions et procedes permettant de cibler et de former une image de tissu chez un sujet vertebre | |
WO2008063291A3 (fr) | Ligands polypeptidiques ciblant le cartilage et procédés d'utilisation de ceux-ci | |
WO2009009203A3 (fr) | Compositions à base de dendrimères et procédés pour les utiliser | |
WO2011157741A3 (fr) | Conjugués anticorps humain-médicament contre le facteur tissulaire | |
WO2011106788A3 (fr) | Peptide car pour le homing, le diagnostic, & la thérapie ciblée pour les troubles pulmonaires et fibrotiques | |
LT2529622T (lt) | Brutono tirozinkinazės inhibitoriai | |
JP2016522261A5 (fr) | ||
WO2005051315A3 (fr) | Lieurs a clivage selectif pour de conjugues radio-immunologiques pour l'imagerie et la therapie du cancer | |
EA032908B1 (ru) | Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7 | |
WO2006027693A3 (fr) | Genes et arn variants specifiques de tumeur et leurs utilisations comme cibles pour le traitement et le diagnostic du cancer | |
WO2011028334A3 (fr) | Synthèse et isolement de systèmes dendrimères | |
WO2011002852A3 (fr) | Complexes de pro-médicaments et leurs procédés d'utilisation | |
EP1708751A4 (fr) | Procedes d'elimination de cellules tumorales par ciblage d'antigene interne expose sur des cellules tumorales apoptotiques | |
WO2006014999A3 (fr) | Compositions et methodes d'utilisation de modulateurs de nectine 4, de semaphorine 4b, d'igsf9 et de kiaa0152 dans le traitement de maladies | |
MX2023002330A (es) | Anticuerpos anti molecula de adhesion celular 5 relacionada con el antigeno carcinoembrionario (ceacam5) y conjugados y usos de los mismos. | |
WO2007092447A3 (fr) | Procedes et compositions lies au ciblage de tumeurs et de plaies |